Ovarian Cancer (OC)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 56 12 74 52 25 58 73 36 29 54 6 42 3 15
Ovarian Carcinoma 12 52 25 54 15 17 71
Ovarian Neoplasms 54 6 43
Ovarian Neoplasm 12 17 71
Malignant Neoplasm of Ovary 71 32
Epithelial Ovarian Cancer 73 71
Neoplasm of Ovary 29 6
Ovarian Cancers 6 15
Primary Malignant Neoplasm of Ovary 71
Malignant Neoplasm of the Ovary 25
Malignant Tumor of the Ovary 25
Malignant Tumour of Ovary 12
Ovarian Cancer, Somatic 56
Malignant Ovarian Tumor 12
Ovarian Malignant Tumor 58
Primary Ovarian Cancer 12
Cancer of the Ovary 25
Tumor of the Ovary 12
Ovarian Carcinomas 15
Cancer, Ovarian 39
Ovary Neoplasm 12
Oc 73


Orphanet epidemiological data:

ovarian cancer
Prevalence: 1-5/10000 (Europe);


somatic mutation


ovarian cancer:
Inheritance autosomal dominant inheritance somatic mutation


Orphanet: 58  
Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology 12 DOID:2394 DOID:4001
OMIM 56 167000
KEGG 36 H00027
ICD9CM 34 183.0
MeSH 43 D010051
NCIt 49 C4984 C7431
SNOMED-CT 67 123843001 363443007
ICD10 32 C56
UMLS via Orphanet 72 C1140680
Orphanet 58 ORPHA213500
UMLS 71 C0029925 C0677886 C0919267 more

Summaries for Ovarian Cancer

Genetics Home Reference : 25 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60. The most common form of ovarian cancer begins in epithelial cells, which are the cells that line the surfaces and cavities of the body. These cancers can arise in the epithelial cells on the surface of the ovary. However, researchers suggest that many or even most ovarian cancers begin in epithelial cells on the fringes (fimbriae) at the end of one of the fallopian tubes, and the cancerous cells migrate to the ovary. Cancer can also begin in epithelial cells that form the lining of the abdomen (the peritoneum). This form of cancer, called primary peritoneal cancer, resembles epithelial ovarian cancer in its origin, symptoms, progression, and treatment. Primary peritoneal cancer often spreads to the ovaries. It can also occur even if the ovaries have been removed. Because cancers that begin in the ovaries, fallopian tubes, and peritoneum are so similar and spread easily from one of these structures to the others, they are often difficult to distinguish. These cancers are so closely related that they are generally considered collectively by experts. In about 10 percent of cases, ovarian cancer develops not in epithelial cells but in germ cells, which are precursors to egg cells, or in hormone-producing ovarian cells called granulosa cells. In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer. In some cases, cancerous tumors can invade surrounding tissue and spread to other parts of the body. If ovarian cancer spreads, cancerous tumors most often appear in the abdominal cavity or on the surfaces of nearby organs such as the bladder or colon. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. Some ovarian cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases. Because it is often diagnosed at a late stage, ovarian cancer can be difficult to treat; it leads to the deaths of about 14,000 women annually in the United States, more than any other gynecological cancer. However, when it is diagnosed and treated early, the 5-year survival rate is high.

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and breast cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are MicroRNAs in cancer and ERK Signaling. The drugs Diclofenac and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and testes, and related phenotypes are abnormality of metabolism/homeostasis and breast carcinoma

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

NIH Rare Diseases : 52 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome , Lynch syndrome and Peutz-Jeghers syndrome ) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy , radiation therapy , and/or targeted therapy (such as monoclonal antibody therapy).

OMIM : 56 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000)

MedlinePlus : 42 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. When ovarian cancer is found in its early stages, treatment works best. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you. Symptoms may be caused by something other than cancer, but the only way to know is to see your doctor, nurse, or other health care professional. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome, raise ovarian cancer risk. Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, occurring in about 70% of ovarian cancer cases.

KEGG : 36 Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.

Novus Biologicals : 55 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 73 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 74 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1368)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 37.6 TP53 RAD51D RAD51C PTEN PMS2 MSH6
2 breast cancer 36.6 TP53 RAD51D RAD51C PTEN PMS2 PIK3CA
3 lynch syndrome 36.4 TP53 RAD51D RAD51C PTEN PMS2 PIK3CA
4 breast-ovarian cancer, familial 1 36.3 RAD51C MSH6 MSH2 BRCA2 BRCA1
5 pancreatic cancer 35.8 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
6 hereditary site-specific ovarian cancer syndrome 35.4 RAD51D RAD51C BRCA2 BRCA1
7 breast-ovarian cancer, familial 2 35.2 BRCA2 BRCA1
8 fallopian tube carcinoma 35.1 TP53 RAD51D RAD51C PTEN ERBB2 BRCA2
9 endometrial cancer 35.1 TP53 PTEN PMS2 PIK3CA MSH6 MSH2
10 familial ovarian cancer 35.0 BRCA2 BRCA1
11 familiar ovarian carcinoma 34.9 PIK3CA BRCA1
12 ovarian disease 34.8 TP53 PTEN ERBB2 CTNNB1 BRCA2 BRCA1
13 ovary epithelial cancer 34.8 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
14 colorectal cancer 34.7 TP53 PTEN PMS2 PIK3CA MSH6 MSH2
15 adenocarcinoma 34.7 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
16 ovarian clear cell carcinoma 34.5 TP53 PTEN PIK3CA KRAS
17 serous cystadenocarcinoma 34.4 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
18 ovary adenocarcinoma 34.3 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
19 prostate cancer 34.3 TP53 PTEN PMS2 PIK3CA MSH6 MSH2
20 glioblastoma multiforme 34.1 TP53 PTEN PMS2 PIK3CA MSH2 KRAS
21 ovarian serous cystadenocarcinoma 34.1 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
22 li-fraumeni syndrome 34.1 TP53 RAD51D RAD51C PTEN PMS2 MSH6
23 lung cancer 34.0 TP53 PTEN PRKN PIK3CA KRAS ERBB2
24 fanconi anemia, complementation group a 33.9 TP53 RAD51D RAD51C PRKN PMS2 MSH6
25 leukemia, acute myeloid 33.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
26 gastric cancer 33.7 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
27 uterine corpus cancer 33.7 TP53 PTEN PMS2 PIK3CA MSH6 MSH2
28 bladder cancer 33.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
29 lung cancer susceptibility 3 33.6 TP53 PTEN PRKN PIK3CA KRAS ERBB2
30 ovarian cystadenocarcinoma 33.6 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
31 cystadenocarcinoma 33.6 TP53 PIK3CA ERBB2 BRCA1 BRAF AKT1
32 cervical cancer 33.4 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
33 neuroblastoma 33.4 TP53 PTEN PRKN PIK3CA MSH2 ERBB2
34 hepatocellular carcinoma 33.4 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
35 ovary transitional cell carcinoma 33.4 BRCA2 BRCA1
36 adenoma 33.4 TP53 PIK3CA MSH6 MSH2 KRAS CTNNB1
37 atypical teratoid rhabdoid tumor 33.3 TP53 CTNNB1 BRCA2
38 bilateral breast cancer 33.3 PTEN PIK3CA MSH6 ERBB2 CHEK2 CDH1
39 in situ carcinoma 33.3 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
40 lymphoma 33.3 TP53 PMS2 PIK3CA MSH6 MSH2 CHEK2
41 esophageal cancer 33.3 TP53 PTEN PIK3CA MSH2 KRAS ERBB2
42 cowden syndrome 33.3 TP53 RAD51D RAD51C PTEN PMS2 PIK3CA
43 pancreatic adenocarcinoma 33.2 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
44 melanoma 33.2 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
45 sporadic breast cancer 33.1 TP53 RAD51C PTEN ERBB2 CHEK2 CDH1
46 medulloblastoma 33.1 TP53 PTEN PIK3CA MSH6 MSH2 ERBB2
47 brain cancer 33.1 TP53 PTEN PMS2 PIK3CA MSH6 MSH2
48 squamous cell carcinoma 33.0 TP53 PTEN PIK3CA ERBB2 CTNNB1 CHEK2
49 carcinosarcoma 33.0 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
50 colon adenocarcinoma 33.0 TP53 PTEN PMS2 PIK3CA MSH6 KRAS

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:

Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Human phenotypes related to Ovarian Cancer:

# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 breast carcinoma 31 HP:0003002
3 dysgerminoma 31 HP:0100621
4 ovarian papillary adenocarcinoma 31 HP:0006774

Symptoms via clinical synopsis from OMIM:

ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM:


UMLS symptoms related to Ovarian Cancer:

pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.8 KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.8 KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.8 KRAS
4 Decreased viability GR00106-A-0 10.8 KRAS
5 Decreased viability GR00221-A-1 10.8 AKT1 KRAS PIK3CA CDH1
6 Decreased viability GR00221-A-2 10.8 AKT1 BRCA1 CHEK2 KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.8 AKT1 BRCA1 CHEK2 ERBB2
8 Decreased viability GR00221-A-4 10.8 AKT1 CHEK2 PIK3CA BRAF ERBB2
9 Decreased viability GR00249-S 10.8 AKT1 BRAF
10 Decreased viability GR00301-A 10.8 BRCA1 KRAS BRAF CDH1 MSH2
11 Decreased viability GR00342-S-2 10.8 CHEK2
12 Decreased viability GR00381-A-1 10.8 KRAS BRAF
13 Decreased viability GR00402-S-2 10.8 PIK3CA CDH1
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.16 AKT1 BRCA1 BRCA2 PTEN
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.16 AKT1 BRCA1 BRCA2 FANCM PRKN PTEN
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.16 BRCA1 BRCA2 CHEK2 RAD51D TP53 MSH2
17 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 CHEK2 FANCM PRKN RAD51D TP53
18 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 AKT1 BRAF BRCA1 CHEK2 FANCM PTEN
19 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10.13 BRAF BRCA1 BRCA2 FANCM RAD51D TP53
20 Decreased cell migration GR00055-A-1 9.5 AKT1
21 Decreased cell migration GR00055-A-3 9.5 BRAF PIK3CA
22 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRAF BRCA1 BRCA2 MSH2 RAD51D

MGI Mouse Phenotypes related to Ovarian Cancer:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
2 homeostasis/metabolism MP:0005376 10.48 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
3 endocrine/exocrine gland MP:0005379 10.45 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
4 mortality/aging MP:0010768 10.45 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
5 growth/size/body region MP:0005378 10.41 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
6 embryo MP:0005380 10.4 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
7 cardiovascular system MP:0005385 10.38 AKT1 BRAF BRCA1 CDH1 CTNNB1 ERBB2
8 immune system MP:0005387 10.38 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
9 hematopoietic system MP:0005397 10.37 AKT1 BRAF BRCA1 BRCA2 CHEK2 CTNNB1
10 integument MP:0010771 10.37 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
11 neoplasm MP:0002006 10.34 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
12 digestive/alimentary MP:0005381 10.33 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
13 nervous system MP:0003631 10.25 AKT1 BRAF BRCA1 BRCA2 CHEK2 CTNNB1
14 limbs/digits/tail MP:0005371 10.16 BRAF BRCA1 BRCA2 CTNNB1 ERBB2 KRAS
15 muscle MP:0005369 10.16 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
16 liver/biliary system MP:0005370 10.1 AKT1 BRAF CTNNB1 FANCM KRAS PMS2
17 normal MP:0002873 10.06 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
18 reproductive system MP:0005389 10.03 AKT1 BRAF BRCA1 BRCA2 CDH1 CHEK2
19 no phenotypic analysis MP:0003012 9.97 CDH1 CTNNB1 FANCM KRAS OPCML PIK3CA
20 pigmentation MP:0001186 9.73 BRAF BRCA1 CTNNB1 KRAS PTEN TP53
21 respiratory system MP:0005388 9.61 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
22 skeleton MP:0005390 9.36 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2

Drugs & Therapeutics for Ovarian Cancer

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 581)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
Fosaprepitant Approved Phase 4 172673-20-0 219090
Ferrous fumarate Approved Phase 4 141-01-5
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Remifentanil Approved Phase 4 132875-61-7 60815
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
19 neurokinin A Phase 4
Substance P Phase 4 33507-63-0 44359816
21 Progestins Phase 4
22 Follicle Stimulating Hormone Phase 4
Apatinib Phase 4 811803-05-1
24 Anesthetics Phase 4
25 Hypnotics and Sedatives Phase 4
26 Anesthetics, General Phase 4
27 Anesthetics, Intravenous Phase 4
28 Anesthetics, Inhalation Phase 4
29 Platelet Aggregation Inhibitors Phase 4
30 Antipyretics Phase 4
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
Hydralazine Approved Phase 3 86-54-4 3637
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
Epirubicin Approved Phase 3 56420-45-2 41867
Ethanol Approved Phase 3 64-17-5 702
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
Goserelin Approved Phase 3 65807-02-5 5311128 47725
Tranexamic Acid Approved Phase 3 1197-18-8 5526
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
Adenosine Approved, Investigational Phase 3 58-61-7 60961
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
Ifosfamide Approved Phase 3 3778-73-2 3690
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
Tamoxifen Approved Phase 3 10540-29-1 2733526

Interventional clinical trials:

(show top 50) (show all 2410)
# Name Status NCT ID Phase Drugs
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
4 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
5 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
6 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
7 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
8 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
9 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
10 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
11 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
12 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
13 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
14 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
15 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
16 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
17 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
18 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
19 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
20 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
21 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
22 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
23 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
24 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Not yet recruiting NCT04352439 Phase 4 Aspirin
25 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
26 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
27 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
28 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
29 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
30 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
31 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
32 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
33 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
34 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Unknown status NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery
35 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
36 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
37 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
38 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
39 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
40 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
41 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
42 Phase 3 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
43 Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23 Unknown status NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
44 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
45 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
46 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
47 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
48 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
49 Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
50 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Chromic phosphate P32
doxorubicin hydrochloride liposome
Leuprolide Acetate
Melphalan hydrochloride
Topotecan Hydrochloride
Uracil Mustard
Vinorelbine tartrate

Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 29 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 29

Anatomical Context for Ovarian Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:


MalaCards organs/tissues related to Ovarian Cancer:

Breast, Ovary, Testes, T Cells, Lung, Lymph Node, Prostate

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 42322)
# Title Authors PMID Year
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. 56 6 61
12819783 2003
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 6 56
12719539 2003
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. 61 54 56
19635727 2010
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. 56 61 54
15619626 2005
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. 56 54 61
11179017 2001
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. 56 61 54
10577927 1999
DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. 56 61 54
9620555 1998
Whole-genome characterization of chemoresistant ovarian cancer. 56 61
26017449 2015
NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. 61 6
23188549 2013
Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. 6 61
22964825 2012
Mutations in BRIP1 confer high risk of ovarian cancer. 56 61
21964575 2011
Integrated genomic analyses of ovarian carcinoma. 61 56
21720365 2011
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. 54 46 61
20461750 2010
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 61 56
19304784 2009
Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. 61 56
19270026 2009
Dicer, Drosha, and outcomes in patients with ovarian cancer. 61 56
19092150 2008
Histologic subtypes of ovarian carcinoma: an overview. 61 56
18317227 2008
Classification of ovarian cancer: a genomic analysis. 61 56
18546616 2008
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. 61 56
18026186 2008
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. 46 61 54
18199536 2008
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 54 6
17611497 2007
Mutation of the PIK3CA gene in ovarian and breast cancer. 54 6
15520168 2004
Alterations in the common fragile site gene Parkin in ovarian and other cancers. 54 56
14614460 2003
Identification of prognostic factors in advanced epithelial ovarian carcinoma. 61 56
11520151 2001
Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. 61 56
9826475 1998
Is hereditary site-specific ovarian cancer a distinct genetic condition? 56 61
9450858 1998
A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. 56 61
8603384 1996
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. 56 54
7942844 1994
A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. 6 61
8052619 1994
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. 56 61
8314147 1994
Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. 61 56
1394208 1992
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. 61 56
2250917 1990
An oncogenic chromosome 8-9 gene fusion isolated following transfection of human ovarian carcinoma cell line DNA. 61 56
1973829 1990
Cytogenetic studies in ovarian cancer. 61 56
6690026 1984
Familial ovarian carcinoma. 56 61
4320145 1970
Familial ovarian cancer. 56 61
4184107 1969
Contribution of xeroderma pigmentosum complementation group D gene polymorphisms in breast and ovarian cancer susceptibility: A protocol for systematic review and meta analysis. 61 42
32481313 2020
Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report. 42 61
32443311 2020
Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. 6
31130282 2019
Germline-Activating RRAS2 Mutations Cause Noonan Syndrome. 6
31130285 2019
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. 56
31043742 2019
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. 6
24493721 2014
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. 56
23467088 2013
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012

Variations for Ovarian Cancer

ClinVar genetic disease variations for Ovarian Cancer:

6 (show top 50) (show all 712) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_001126112.2(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
3 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
4 PTEN NM_000314.7(PTEN):c.1027-1G>ASNV Pathogenic 372482 rs1057517809 10:89725043-89725043 10:87965286-87965286
5 TP53 NM_001126112.2(TP53):c.626_627del (p.Arg209fs)deletion Pathogenic 372539 rs1057517840 17:7578222-7578223 17:7674904-7674905
6 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
7 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
8 TP53 NM_001126112.2(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
9 PALB2 NM_024675.3(PALB2):c.2296_2297del (p.Val767fs)deletion Pathogenic 229748 rs876658170 16:23641178-23641179 16:23629857-23629858
10 RAD51D NM_133629.3(RAD51D):c.145-630_145-627deldeletion Pathogenic 229953 rs876658297 17:33434127-33434130 17:35107108-35107111
11 TP53 NM_001126112.2(TP53):c.976G>T (p.Glu326Ter)SNV Pathogenic 231815 rs876659384 17:7576870-7576870 17:7673552-7673552
12 TP53 NM_001126112.2(TP53):c.454_466del (p.Pro152fs)deletion Pathogenic 231540 rs876659215 17:7578464-7578476 17:7675146-7675158
13 TP53 NM_001126112.2(TP53):c.273G>A (p.Trp91Ter)SNV Pathogenic 233650 rs876660548 17:7579414-7579414 17:7676096-7676096
14 TP53 NM_001126112.2(TP53):c.158G>A (p.Trp53Ter)SNV Pathogenic 230285 rs876658483 17:7579529-7579529 17:7676211-7676211
15 CDH1 NM_004360.5(CDH1):c.220C>T (p.Arg74Ter)SNV Pathogenic 239891 rs876658932 16:68835629-68835629 16:68801726-68801726
16 BRCA1 NM_007294.4(BRCA1):c.65T>A (p.Leu22Ter)SNV Pathogenic 252428 rs80357438 17:41276049-41276049 17:43124032-43124032
17 BRCA1 NM_007294.4(BRCA1):c.4932_4933dup (p.Arg1645fs)duplication Pathogenic 254459 rs80357833 17:41222997-41222998 17:43070980-43070981
18 BRCA1 NM_007294.4(BRCA1):c.397del (p.Arg133fs)deletion Pathogenic 254374 rs886037973 17:41256183-41256183 17:43104166-43104166
19 CTNNB1 NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter)SNV Pathogenic 265443 rs775104326 3:41266486-41266486 3:41224995-41224995
20 BRCA2 NM_000059.3(BRCA2):c.2399dup (p.Gly800_Asn801insTer)duplication Pathogenic 266696 rs886040423 13:32910889-32910890 13:32336752-32336753
21 BRCA2 NM_000059.3(BRCA2):c.6385G>T (p.Glu2129Ter)SNV Pathogenic 266943 rs886040653 13:32914877-32914877 13:32340740-32340740
22 BRCA1 NM_007294.4(BRCA1):c.342del (p.Pro115fs)deletion Pathogenic 266370 rs886040129 17:41256238-41256238 17:43104221-43104221
23 BRCA1 NM_007294.3(BRCA1):c.5333-1G>TSNV Pathogenic 267600 rs80358126 17:41201212-41201212 17:43049195-43049195
24 BRCA1 NM_007294.3(BRCA1):c.212G>C (p.Arg71Thr)SNV Pathogenic 267512 rs80356913 17:41258473-41258473 17:43106456-43106456
25 TP53 NM_001126112.2(TP53):c.644G>T (p.Ser215Ile)SNV Pathogenic 376660 rs587782177 17:7578205-7578205 17:7674887-7674887
26 TP53 NM_001126112.2(TP53):c.722C>A (p.Ser241Tyr)SNV Pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
27 TP53 NM_001126112.2(TP53):c.517G>T (p.Val173Leu)SNV Pathogenic 376668